Telomir Pharmaceuticals, Inc. Annual Report - A Deep Dive for Investors

Dive into Telomir Pharmaceuticals, Inc.'s (ticker: TELO) fiscal year 2025 performance. This summary distills their recent 10-K filing, offering a clear, jargon-free look at their progress, financial health, and future prospects to help you assess if it fits your investment strategy.

1. Business Overview: What does this company do?

Telomir Pharmaceuticals, Inc. is an early-stage pharmaceutical company that develops novel product candidates. Its primary focus is Telomir-1, a compound licensed for development in the United States. Telomir-1 targets age-related diseases in both humans and pets. During the past year, Telomir advanced Telomir-1 into a Phase 1/2 clinical trial for idiopathic pulmonary fibrosis. The company also navigated the complexities of operating as a newly public entity.

2. Financial Performance & Funding

Now, let's examine Telomir's financial performance and how it funds its operations. For the fiscal year ended December 31, 2025, Telomir remained a pre-revenue company, generating no income from product sales. Its focus on research and development (R&D) led to a net loss of approximately $25.5 million for the year. R&D expenses were a significant driver of this loss, totaling around $18.3 million as the company invested in advancing Telomir-1 through clinical trials.

To fund its operations, the company relied entirely on capital raises. A significant milestone was its Initial Public Offering (IPO) in February 2024, which raised approximately $15.0 million (net of expenses) to fund operations. Beyond the IPO, Telomir also used an "At-The-Market" (ATM) offering—which allows companies to sell shares directly into the market over time—and private placements.

As of December 31, 2025, Telomir held approximately $12.8 million in cash and cash equivalents. The company's market capitalization was approximately $18.1 million as of June 30, 2025, with shares trading around $1.25 each. As of March 12, 2026, the company had approximately 34.4 million shares of common stock outstanding.

3. Management's Discussion & Analysis (MD&A) Highlights

Management offers its own perspective on these results and future plans in the MD&A.

Results of Operations: In fiscal year 2025, Telomir Pharmaceuticals, Inc. continued operating as a pre-revenue, clinical-stage biopharmaceutical company. The company reported a net loss of approximately $25.5 million, primarily driven by significant investments in research and development (R&D) activities. R&D expenses amounted to approximately $18.3 million, reflecting the costs associated with advancing Telomir-1 into a Phase 1/2 clinical trial for idiopathic pulmonary fibrosis. General and administrative expenses also contributed to the loss, reflecting the operational demands of a newly public company. Management's focus remains on Telomir-1's clinical progression and strategic initiatives to enhance the company's long-term value.

Liquidity and Capital Resources: As of December 31, 2025, the company's liquidity position included approximately $12.8 million in cash and cash equivalents. The company primarily sourced this capital from its Initial Public Offering (IPO) in February 2024, which generated approximately $15.0 million (net), supplemented by proceeds from an "At-The-Market" (ATM) offering and private placements. Management acknowledges the company's recurring losses and negative cash flows from operations. This raises "substantial doubt" about its ability to continue as a going concern without securing significant additional financing. The company has minimal long-term debt but faces increasing capital requirements to fund its ongoing R&D programs and clinical trials. Management anticipates the necessity of raising substantial additional capital through equity offerings or other financing mechanisms to sustain operations and further develop its product candidates.

Strategic Developments and Outlook: Management highlights a significant strategic development: the proposed merger with TELI Pharmaceuticals, Inc. The company views this initiative as a critical step to broaden its product pipeline, combine resources, and potentially accelerate development efforts, aligning with its long-term growth strategy. Management's future outlook centers on the successful advancement of Telomir-1 through clinical development and the successful integration and realization of synergies from the proposed merger.

4. Financial Health & Liquidity

Delving deeper into the numbers, Telomir's financial health presents specific challenges. The company explicitly states there is "substantial doubt as to our ability to continue as a going concern" due to recurring losses and negative cash flows from operations. This means that without securing significant additional financing, uncertainty exists about their ability to meet future obligations and continue operations beyond the next 12 months.

As of December 31, 2025, the company had $12.8 million in cash and cash equivalents. Given its current burn rate, this cash balance provides a limited runway. Telomir has minimal debt but faces "significant and increasing liquidity needs" to fund ongoing R&D and clinical trials. The company must raise substantial additional financing through equity offerings or other means to sustain operations and advance Telomir-1.

5. Risk Factors

As with any early-stage biotech, investing in Telomir comes with significant risks:

• Product Concentration Risk: Its future success depends heavily on the successful development and commercialization of Telomir-1. Failure in clinical trials, regulatory approval, or market adoption would severely impact the company.
• "Going Concern" Risk: The most immediate financial risk is the "substantial doubt" about their ability to continue operations. Failure to raise additional capital could lead to insolvency or significant dilution for existing shareholders.
• Clinical Trial Failure & Regulatory Hurdles: Drug development is inherently risky. Telomir-1's Phase 1/2 clinical trial could fail, or even if successful, obtaining regulatory approval from the FDA is a lengthy, expensive, and unpredictable process with a high rate of failure for drug candidates.
• No Revenue, No Profitability: As a pre-revenue company, Telomir is not profitable and will continue to incur losses for the foreseeable future, relying solely on external funding.
• Intellectual Property (IP) Risk: Telomir-1, the company's core asset, relies on licensed intellectual property (IP). Challenges to this license, inability to protect their own IP, or claims of infringement could significantly harm their business.
• Dependence on Third Parties: Telomir relies on contract research organizations (CROs) for clinical trials and contract manufacturing organizations (CMOs) for drug production. Poor performance or termination of these relationships could cause significant delays.
• Intense Competition: The pharmaceutical industry is highly competitive, with larger, well-established companies possessing significantly greater financial, technical, and human resources.
• Merger-Specific Risks: The proposed merger with TELI Pharmaceuticals, Inc. introduces integration risks, potential cultural clashes, and the risk that the anticipated benefits (e.g., expanded pipeline) may not materialize. TELI is also an early-stage company with similar risks.
• Insider Control & Conflicts of Interest: Founding stockholders, officers, and directors control a significant portion of the company's stock, potentially influencing decisions in ways that may not always align with all shareholders' interests. Potential conflicts of interest exist with MIRALOGX, an entity controlled by Telomir's CEO, which provides certain services to Telomir.
• Highly Speculative Investment: Given all these factors, an investment in Telomir is considered highly speculative, with a substantial risk of losing your entire investment.

6. Competitive Position

Understanding Telomir's competitive landscape is crucial. Telomir operates in a highly competitive segment of the pharmaceutical industry, particularly in the development of treatments for age-related diseases. They face "intense competition" from established pharmaceutical giants, larger biotechnology companies, and academic institutions. These competitors often have "greater financial resources, more extensive R&D capabilities, and more experienced marketing and sales teams." Telomir currently has limited internal marketing experience and does not plan to build its own sales force, which could be a disadvantage if Telomir-1 reaches commercialization.

7. Major Milestones & Challenges

Despite the financial challenges, Telomir has achieved key milestones while facing significant hurdles.

Major Milestones:

• Successful IPO: Completed its IPO in February 2024, raising crucial capital of approximately $15.0 million (net) and establishing itself as a public entity.
• Clinical Advancement: Advanced Telomir-1 into a Phase 1/2 clinical trial for idiopathic pulmonary fibrosis, a critical step in drug development.
• Strategic Merger Announcement: Proposed a merger with TELI Pharmaceuticals, Inc., a strategic move to enhance its pipeline and operational capabilities.
• Intellectual Property: Secured a U.S. license for Telomir-1 for both human and pet applications, forming the core of its product pipeline.

Major Challenges:

• Significant Net Loss & No Revenue: The company incurred a substantial net loss of $25.5 million with no product sales, typical for biotech but highlighting reliance on external funding.
• "Going Concern" Doubt: Auditors expressed "substantial doubt" about the company's ability to continue operating without securing significant additional funding, a serious financial warning.
• High Burn Rate: R&D expenses of $18.3 million and general operating costs mean the company is rapidly consuming its cash reserves.
• Limited Operating History: As a relatively new public company, it has a short track record for investors to evaluate, increasing investment uncertainty.

8. Future Outlook & Strategic Direction

Looking ahead, Telomir's strategy hinges on several critical factors. Its future outlook is entirely dependent on the successful and timely development, regulatory approval, and eventual commercialization of its product candidates, primarily Telomir-1. The company aims to advance Telomir-1 through its Phase 1/2 clinical trial and subsequent phases. The proposed merger with TELI Pharmaceuticals, Inc. is a cornerstone of its future strategy, aiming to create a more robust company with a diversified pipeline. This could lead to a restructured leadership team and a revised corporate strategy post-merger.

However, the path to commercialization is exceptionally long, expensive, and uncertain, with no guarantee of success or profitability. The company will need to continue raising significant amounts of additional capital to fund these efforts, which will likely result in further shareholder dilution. The company notes that some executive officers are not full-time employees, which could raise questions about dedicated oversight. Furthermore, potential "conflicts of interest" exist with MIRALOGX, an entity controlled by Telomir's CEO that provides services to Telomir. This relationship requires careful monitoring to ensure decisions are made in the best interest of all shareholders.

9. Market Trends & Regulatory Environment

Finally, external factors like market trends and the regulatory environment heavily influence Telomir's trajectory. As a pharmaceutical company, Telomir is heavily influenced by the regulatory environment, particularly the U.S. Food and Drug Administration (FDA). The report emphasizes the drug approval process is "lengthy, complex, and inherently unpredictable," offering no clear timeline for product approval. Changes in regulatory policies, increased scrutiny, or new requirements could significantly impact their development timelines and costs. Broader market trends, such as public health priorities, economic conditions, and investor appetite for early-stage biotech, also play a crucial role in their ability to raise capital and attract talent.